Funding for this research was provided by:
KWF Kankerbestrijding (RUG 2001-2361, RUG 2011-5156, RUG 2009-4579, RUG 2009-4549, RUG 2008-4066)
Text and Data Mining valid from 2018-11-21
Received: 2 May 2018
Accepted: 9 November 2018
First Online: 21 November 2018
Compliance with ethical standards
: Toos Daemen is founder of ViciniVax, a spin-off company of the UMCG, developing therapeutic cancer vaccines. All other authors declare that they have no conflict of interest.
: All animal experiments reported in this article were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Groningen and were performed in accordance with the national and/or institutional guidelines for the care and use of animals. Clinical trial: Vvax001 FIH trial: NCT number: NCT03141463. EudraCT Number: 2015-004979-74. Ethics committee: Centrale Commissie Mensgebonden Onderzoek (CCMO), The Netherlands. Institutional Review Board: Medical Ethical Committee (METc).
: Informed consent was obtained from all individual participants included in the study.